HUTCHMED (China) Ltd has made a significant announcement regarding its regulatory progress. The company revealed that its filings for ORPATHYS and TAGRISSO have been accepted for review in Europe and Japan. This development is crucial as it follows the recent submission of a New Drug Application (NDA) to the US FDA in September 2026, marking a pivotal moment for the company in the global pharmaceutical landscape.

HUTCHMED, listed on Nasdaq and OTC under the ticker symbols HCM and HMDCF, operates within the pharmaceutical preparations sector, specifically focusing on innovative cancer therapies. The company has been actively involved in advancing treatments for patients with non-small cell lung cancer (NSCLC), particularly those with MET-driven mutations.

The latest filing, dated November 2, 2026, highlights that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) submitted by AstraZeneca for the combination of ORPATHYS and TAGRISSO. This combination is aimed at treating patients with advanced or metastatic NSCLC whose tumors exhibit MET overexpression or amplification after progression on EGFR TKI therapy.

In Japan, AstraZeneca has also submitted an NDA to the Ministry of Health, Labour and Welfare, which has been accepted for review. This marks a significant step in expanding the availability of this innovative treatment, which has shown promising results in clinical trials.

The regulatory filings are backed by positive data from the SAFFRON global Phase III trial. This trial demonstrated statistically significant improvements in progression-free survival (PFS) and overall survival (OS) for patients treated with the combination of ORPATHYS and TAGRISSO compared to traditional chemotherapy options. The results were presented at the European Society for Medical Oncology (ESMO) Congress 2026 and published in The New England Journal of Medicine.

According to the trial data, the combination reduced the risk of disease progression or death by 45% compared to chemotherapy, with median PFS extending to 7.6 months. Additionally, the treatment reduced the risk of death by 32%, extending median OS by 4.9 months compared to the comparator arm.

This announcement is expected to impact various stakeholders, including patients with advanced NSCLC who may benefit from this new treatment option, healthcare providers, and investors in the pharmaceutical sector. HUTCHMED's collaboration with AstraZeneca on this project further emphasizes the importance of partnerships in developing effective cancer therapies.

As of now, the next steps for HUTCHMED remain unclear following this filing. The company did not specify any upcoming votes or additional filings in the announcement. However, the acceptance of these regulatory filings represents a crucial milestone in HUTCHMED's ongoing efforts to bring innovative therapies to market.